secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2026-06-29T12:32:15+00:00
Accession:  0001193125-26-286918
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evommune EVO756 Phase 2b misses primary endpoint in CSU; development halted for that indication
--------------------------------------------------------------------------------

- Phase 2b trial of EVO756 in 160 CSU patients did not meet primary endpoint of UAS7 change at 12 weeks at any dose.
- Company will cease EVO756 development for CSU but will continue evaluation in atopic dermatitis and migraine.
- Top-line Phase 2b data for EVO756 in atopic dermatitis expected Q3 2026; migraine trial screening initiated.
- Cash position supports anticipated operations through 2028; EVO301 Phase 2b for AD in planning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526286918/0001193125-26-286918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526286918/evmn-20260629.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-286918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer